Q-omics provides the consensus-scored ZC3H6 profile across patient tissues and cancer cell-line models. ZC3H6 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, ZC3H6 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, ZC3H6 RNA expression shows 21,527 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight SKCM, THCA, and THYM as cancer lineages where ZC3H6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZC3H6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZC3H6 survival associations across molecular data types. ZC3H6 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZC3H6 RNA expression–survival associations across cancer types. High ZC3H6 expression shows favorable associations in SKCM, BRCA, KIRC, HNSC, CHOL and ACC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for ZC3H6 RNA expression.
This table summarizes ZC3H6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 4. The strongest signals are observed in THCA for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ZC3H6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZC3H6 shows lower tumor expression in THCA, UCEC, BRCA and LUSC and higher tumor expression in CHOL and LIHC. The THCA box plot shows higher ZC3H6 RNA expression in normal versus tumor tissue (log2 FC = −0.470, t-test p < 0.001).
This table shows molecular features associated with ZC3H6 in patient tissues and cancer cell lines. In patient samples, ZC3H6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ZC3H6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
